Signal transduction pathway analysis in desmoid-type fibromatosis: Transforming growth factor-β, COX2 and sex steroid receptors

Testosterone regulates cell proliferation in aggressive fibromatosis (desmoid tumour)

(2011) H Hong et al.   BRITISH JOURNAL OF CANCER

Suppression of TGF-β1/SMAD pathway and extracellular matrix production in primary keloid fibroblasts by curcuminoids: its potential therapeutic use in the chemoprevention of keloid

(2010) Yi-Chiang Hsu et al.   ARCHIVES OF DERMATOLOGICAL RESEARCH

Role of Radiotherapy in the Management of Desmoid Tumors

(2010) Iris Gluck et al.   INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS

The dynamic roles of TGF-β in cancer

(2010) Erik Meulmeester et al.   JOURNAL OF PATHOLOGY

Desmoids: A Revelation in Biology and Treatment

(2009) Wesley P. Francis et al.   ANNALS OF SURGICAL ONCOLOGY

TGF-β and fibrosis in different organs — molecular pathway imprints

(2009) Dirk Pohlers et al.   BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR BASIS OF DISEASE

Desmoid tumor: from surgical extirpation to molecular dissection

(2009) Alexander JF Lazar et al.   CURRENT OPINION IN ONCOLOGY

Desmoid tumors: need for an individualized approach

(2009) Eelco de Bree et al.   Expert Review of Anticancer Therapy

Successful Treatment With Meloxicam, a Cyclooxygenase-2 Inhibitor, of Patients With Extra-Abdominal Desmoid Tumors: A Pilot Study

(2009) Yoshihiro Nishida et al.   JOURNAL OF CLINICAL ONCOLOGY

The androgen receptor can signal through Wnt/β-Catenin in prostate cancer cells as an adaptation mechanism to castration levels of androgens

(2008) Liang Schweizer et al.   BMC CELL BIOLOGY

Cyclooxygenase-2 Inhibition Inhibits c-Met Kinase Activity and Wnt Activity in Colon Cancer

(2008) J. B. Tuynman et al.   CANCER RESEARCH

A critical analysis of treatment strategies in desmoid tumours: a review of a series of 106 cases

(2008) E. Stoeckle et al.   EJSO

Regulation of Myogenic Differentiation by Androgens: Cross Talk between Androgen Receptor/ β-Catenin and Follistatin/Transforming Growth Factor-β Signaling Pathways

(2008) Rajan Singh et al.   ENDOCRINOLOGY

A new prostate cancer therapeutic approach: Combination of androgen ablation with COX-2 inhibitor

(2008) Yi Cai et al.   INTERNATIONAL JOURNAL OF CANCER

Toremifene decreases type I, type II and increases type III receptors in desmoid and fibroma and inhibits TGFbeta1 binding in desmoid fibroblasts

(2007) Giordano Stabellini et al.   BIOMEDICINE & PHARMACOTHERAPY